Anupam Rasayan India Ltd. · NSE:ANURAS
Anupam Rasayan India — Q3 FY2023 Earnings Presentation
30 slides from Anupam Rasayan India's earnings presentation, Jan 27, 2023
Slide 1: Exchange filing cover letter
ANUPAM RASAYAN INDIA LTD. R Date: January 27, 2023 ARILSLDSTX20230127095 To, To, BSE Limited, Sr. General Manager Phiroze Jeejeebhoy Towers, National Stock Exchange of India Limited Dalal Street, ‘Exchange Plaza’, C-1, Block-G, Mumbai -400001, India Bandra Kurla Complex SCRIP CODE: 543275 Bandra (Ea
Slide 2: Anupam Rasayan India Limited Investor Presentation Q3FY23
ANUPAM RASAYAN INDIA LIMITED INVESTOR PRESENTATION BSE: 543275 | NSE: ANURAS | ISIN: INE930P01018 Q3FY23 ©2020 – Anupam Rasayan India Limited, All Rights Reserved. January 2023
Slide 3: Tables of Contents
Tables of Contents FINANCIALS AND OPERATIONAL UPDATES Slide 03 OUR BUSINESS Slide 16 BOARD OF DIRECTORS Slide 26
Slide 4: Financials and Operational Updates
FINANCIALS AND OPERATIONAL UPDATES Financial Highlights Slide 4 Managing Director’s message Slide 5 Growth Drivers Slide 11
Slide 5: Nine Month Standalone Financial Highlights
FINANCIALS AND OPERATIONAL UPDATES Nine Month Standalone Financial Highlights Operating Revenue was EBITDA (Incl. Other Revenue) was PAT stood at ₹ 1,172 Mn., ₹ 9,035 Mn; Y-o-Y growth of 21% ₹ 2,592 Mn.; Y-o-Y growth of 21% Y-o-Y growth of 11% Added 2 new products in 9MFY23 Cashflow From Operations
Slide 6: Managing Director's Message
Managing Director’s Message Mr. Anand S Desai “I am pleased to inform you that despite unavailability of the certain capacities M A N A G I N G D I R E C TO R during the quarter, we were able to deliver growth on YoY basis. If you adjust the deferred revenue due to capacity constrain then our growth
Slide 7: Consolidated Profit & Loss Summary (Quarterly)
QUARTERLY FINANCIALS Consolidated Profit & Loss Summary (All amounts are in ₹ Mn) Q3FY22 Q3FY23 INCOME Revenue from Operations 2,662 3,827 Other Income 50 60 Total Revenue 2,711 3,888 Total Revenue Growth (%) 43% EXPENSES: Cost of Raw Materials Consumed 900 1,684 Gross Profit 1,761 2,143 Gross Margi
Slide 8: Consolidated Profit & Loss Summary (Nine Month)
NINE MONTH FINANCIALS Consolidated Profit & Loss Summary (All amounts are in ₹ Mn) 9MFY22 9MFY23 INCOME Revenue from Operations 7,488 11,126 Other Income 155 (64) Total Revenue 7,643 11,062 Total Revenue Growth (%) 45% EXPENSES: Cost of Raw Materials Consumed 2,671 4,677 Gross Profit 4,816 6,449 Gro
Slide 9: Standalone Profit & Loss Summary (Quarterly)
QUARTERLY FINANCIALS Standalone Profit & Loss Summary (All amounts are in ₹ Mn) Q3FY22 Q3FY23 INCOME Revenue from Operations 2,662 2,862 Other Income 50 49 Total Revenue 2,711 2,912 Total Revenue Growth (%) 7% EXPENSES: Cost of Raw Materials Consumed 900 1,115 Gross Profit 1,762 1,747 Gross Margins
Slide 10: Standalone Profit & Loss Summary (Nine Month)
NINE MONTH FINANCIALS Standalone Profit & Loss Summary (All amounts are in ₹ Mn) 9MFY22 9MFY23 INCOME Revenue from Operations 7,488 9,035 Other Income 155 (65) Total Revenue 7,643 8,970 Total Revenue Growth (%) 17% EXPENSES: Cost of Raw Materials Consumed 2,680 3,399 Gross Profit 4,808 5,636 Gross M
Slide 11: Operational Updates
FINANCIALS AND OPERATIONAL UPDATES Operational Updates • Restart of plant - On January 04, 2023, the company has restarted the operations in one plant out of the two plants in the unit post receipt of revocation of closure order and approval to restart the plant from the GPCB and other regulatory au
Slide 12: Growth Drivers
FINANCIALS AND OPERATIONAL UPDATES Growth Drivers Growth of Product Execution of Signed LOIs Expansion in Portfolio and Contracts Fluorination chemistry ANUPAM RASAYAN INDIA LIMITED | 11
Slide 13: Growth Of Product Portfolio
FINANCIALS AND OPERATIONAL UPDATES Growth Of Product Portfolio NUMBER OF MOLECULES IN NUMBER OF MOLECULES TO R&D AND PILOT COMMERCIALISED IN FY23 90+ 7 New Strategic Custom Development Products under pipeline to be manufactured by Anupam in India: Agro: • Established Active Ingredients of originator
Slide 14: Execution of Signed LOIs and Contracts
FINANCIALS AND OPERATIONAL UPDATES Execution of Signed LOIs and Contracts Signing Quarter Segment Customer LOI/Contract Tenor (Years) Value(₹ Crores) Multinational Life Science Q1FY22 Life Science LOI 5 ₹1,100 Company Two Multinational Q1FY22 Life Science Contract 5 ₹540 Companies European Multinati
Slide 15: Anupam – Tanfac Integration
FINANCIALS AND OPERATIONAL UPDATES Anupam – Tanfac Integration Anupam acquired ~26% stake in Tanfac for ~₹1,530M in May'22 Backward integration with Tanfac to secure KSM Uninterrupted access to key raw materials (HF and KF) for fluorination chemistry Only Indian Producer of manufacturer of Leading p
Slide 16: Expansion in Fluorination chemistry
FINANCIALS AND OPERATIONAL UPDATES Expansion in Fluorination chemistry Details of Few Molecules out of 14 Identified Segment Revenue Focused Segments Molecules End Application Customer Potential Product A Elastomer US MNC Polymers $ 40 – 70 Mn. Semiconductor/Flame Product B Japanese MNC Retardant Pr
Slide 17: Our Business
OUR BUSINESS Business Verticals and Geographies Slide 17 Key Strength: Customer Stickiness Slide 20 EHS Slide 21 Evolution of Anupam Slide 22 Strong Manufacturing Capabilities Slide 23 Leadership Team Slide 24
Slide 18: About Anupam
About Anupam COMPANY AT A GLANCE Established Custom Synthesis player Specializes in multi-step Catering to globally relevant Strong supply chain with backward with 38 years of track record synthesis undertaking complex chemical & agrochemical integrated facilities chemical reactions to produce key c
Slide 19: Business Verticals
OUR BUSINESS Business Verticals BUSINESS VERTICALS OVERVIEW HISTORICAL BUSINESS PERFORMANCE Revenue from Life Science (In ₹ Mn) Life Science Related Other Specialty 82% Q3 FY 23 2,312 Specialty Chemicals Chemicals Q2 FY 23 2,766 90% Agrochemicals Specialty Pigments (including Crop Protection) Q1 FY
Slide 20: Making a Mark Globally
OUR BUSINESS Making a Mark Globally MANUFACTURING CLIENTELE UNITS IN INDIA GLOBALLY (In Nos.) (In Nos.) 6* 71* REVENUE BY GEOGRAPHY EUROPE 26% EUROPE 30% EUROPE 35% EUROPE 30% INDIA 44% INDIA 38% INDIA 31% INDIA 38% SINGAPORE 11% SINGAPORE 15% SINGAPORE 13% SINGAPORE 15% FY22 JAPAN 12% Q1 Q2 Q3 JAPA
Slide 21: Key Strength: Customer Stickiness
OUR BUSINESS Key Strength: Customer Stickiness FEW OF OUR TOP GLOBAL CLIENTS • Long-standing relationships, clients onboarded after significant gestation period • Stringent customer audits, approvals & requirements adhered too • Dealing with top MNCs around the globe supplying them niche molecules •
Slide 22: EHS at Anupam Rasayan
OUR BUSINESS EHS at Anupam Rasayan WASTE MANAGEMENT ENVIRONMENT MANAGEMENT SAFETY COMMITED TO MAKE POSITIVE IMPACT WE BELIEVE PROTECTING THE WELL BEING COMMITTED TO CONDUCTING ALL OUR ON THE ENVIRONMENT OF OUR EMPLOYEE AND ENVIRONMENT IS OPERATION IN SAFE AND RELIABLE OUR RESPONSIBILITY MANNER • Zer
Slide 23: Evolution of Anupam
OUR BUSINESS Evolution of Anupam Phase I-Inception Phase II- The Acceleration • Fast growing • Formed partnership • Started supplying to • Awarded ‘Green • Commercialized 2 • Started working with Adama Specialty Chemical firm “Anupam Syngenta Innovation Award’ by more manufacturing • Listed on NSE a
Slide 24: Strong Manufacturing and R&D Capabilities
OUR BUSINESS Strong Manufacturing and R&D Capabilities Manufacturing prowess R&D Competencies • DSIR recognized R&D center with a team of 85 R&D professionals ~27,200 MT Manufacturing Capacity, spread over 6 manufacturing facilities • Expertise in executing complex chemistries & multi step synthesis
Slide 25: Experienced Leadership & Deep Technical Talent Pool
OUR BUSINESS Experienced Leadership & Deep Technical Talent Pool Experienced management team Our R&D talent pool Mr. Anand Desai Ms. Mona A Desai Image here Managing Director Over 30 years of experience in Image here Vice- Chairman & Whole- Time Director 85+ 100+ chemicals industry associated Over 2
Slide 26: Experienced Business Development Team
OUR BUSINESS Experienced Business Development Team Europe Mr. Thierry Baumlin Mr. Mauro Principe Mr. Pierre Joris Mr. Oliver Kappe Key Account Manager – Europe Business Development – Fluoro Business Advisor Technical Advisor – Flow Business – Europe Chemistry 30 years+ of experience in 30 years+ of
Slide 27: Board of Directors
BOAD OF DIRECTORS Board of Directors Slide 27
Slide 28: Board of Directors
TEAM Board of Directors DR. KIRAN C PATEL MR. ANAND S DESAI MS. MONA A DESAI MR. MILAN THAKKAR CHAIRMAN & MANAGING DIRECTOR VICE-CHAIRMAN & NON-EXECUTIVE DIRECTOR NON-EXECUTIVE DIRECTOR WHOLE-TIME DIRECTOR • Associated with the company for past • Over 30 years of experience in • Over 20 years of exp
Slide 29: Safe Harbor
Safe Harbor Safe Harbor Certain statements in this presentation concerning our future growth prospects are forward looking statements, which involve a number of risks, and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The company's
Slide 30: Thank You
THANK YOU CONTACT US: MR. VISHAL THAKKAR MR. RAVISH CHAUDHARY Anupam Rasayan India Ltd. investors@anupamrasayan.com MR. RAHUL THKUR MR. DIWAKAR PINGLE EY Investor Relations Rahul.thakur@in.ey.com diwakar.pingle@ey.com CORPORATE OFFICE Anupam Rasayan India Ltd. India (HQ) 8110, Sachin G.I.D.C. Estate
Anupam Rasayan India — Q3 FY2023 Earnings Presentation on 6ix